View Older Stories
-
Intercept Pharmaceuticals (ICPT) Selloff is Overdone - RBC
-
Concerns over Intercept (ICPT) Accelerated Approval is 'Unfounded' - RBC
-
CymaBay (CBAY) Setback a Positive for Intercept Pharmaceuticals (ICPT) - RBC
-
RBC Capital Continues to View Intercept Pharmaceuticals (ICPT) as a Takeover Target
-
Intercept to Present at Upcoming Investor Conferences in May
-
Intercept Pharma (ICPT) Prices Offerings of Common Stock and Convertible Senior Notes due 2026
-
Intercept Pharmaceuticals Announces Pricing of Offerings of Common Stock and Convertible Senior Notes due 2026
-
Intercept Pharmaceuticals (ICPT) Seeing 'Sell-the-News' Reaction, Dataset Positive - RBC
-
Pre-Open Stock Movers 04/11: (FRSH) (VKTX) (LEDS) Higher; (ICPT) (BBBY) (TSLA) Lower (more...)
-
RBC Capital Upgrades Intercept Pharmaceuticals (ICPT) to Outperform Following Bullish Doc Survey
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $130 at RBC Capital
-
Intercept Pharmaceuticals (ICPT) PT Raised to $137 at RBC Capital
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $114 at RBC Capital
-
RBC Capital Downgrades Intercept Pharmaceuticals (ICPT) to Sector Perform
-
Intercept Pharma (ICPT) Ocaliva Deaths In-Line with Norms, No Need to Worry - RBC
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital
-
While Intercept (ICPT) NASH Competitor 'Impresses', ICPT Remains Ahead and is Undervalued - RBC
-
Intercept Pharmaceuticals (ICPT) Could See Upside on Upcoming Competitor NASH Data - RBC
-
Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
-
RBC Capital on Intercept Pharma (ICPT): Benign Label Update Removes Key Overhang, Should Set Stage for Ocaliva Growth
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $200 at RBC Capital
-
RBC Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform
-
Intercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences
-
Pre-Open Stock Movers 10/14: (DGLY) (AMD) (ICPT) Higher; (SMSI) (HIVE) (NTNX) Lower (more...)
-
Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes
-
Pre-Open Stock Movers 06/30: (CRCM) (FVE) (ONE) Higher; (AMPE) (TSCO) (PIR) Lower (more...)
-
Intercept Pharma (ICPT) Prices Aggregate $400M Conv. Notes Offering
-
Intercept Pharmaceuticals Announces Pricing of Public Offering of Convertible Senior Notes
-
After-Hours Stock Movers 06/29: (CRCM) (SGY) (LGF) (STRZA) (C) Higher; (TSCO) (PIR) (ICPT) Lower (more...)
-
Intercept Pharma (ICPT) Announces Aggregate $400M Conv. Senior Notes Offering
-
Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes
-
Notable Analyst Rating Changes 4/8: (EGO) (MXIM) (APA) Upgraded; (AKS) (BOOT) (ICPT) Downgraded
-
Biotech Seen Grinding Higher, Says RBC Capital (IBB)
-
Notable Analyst Rating Changes 12/4: (TEVA) (HBI) (HPP) Upgraded; (M)( GPRO) (KSU) Downgraded
-
Intercept (ICPT) Positive Stance Maintained at RBC as Another PBC Competitor 'Falls to Wayside' (SHPG)
-
Intercept (ICPT) Bearish Concerns Tied to Trial Size; RBC Reiterates Outperform
-
Intercept (ICPT) Shares Likely to Keep Moving Higher, Says RBC
-
Intercept (ICPT) Remains Leader Over Genfit in NASH, Says RBC Capital
-
RBC Capital Comments on Intercept (ICPT) Phase 2b Flint Data
-
AbbVie (ABBV) /Pharmacyclics (PCYC) Deal Bullish for SMID Biotech and Big Drugs, Says RBC
-
RBC Comments on Intercept Pharmaceuticals (ICPT) Ahead of Competitor Data
-
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
-
Intercept Pharma (ICPT) 1M Stock Offering Prices at $176/Share
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Intercept Pharma (ICPT) to Offer 800K Shares
-
Pre-Open Stock Movers 1/30: (BAMM) (ICPT) (AMZN) Higher; (GENE) (DECK) (ALGN) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 1/6: (ICPT) (AMZN) (GPRO) (MPEL)
-
RBC Capital Comments on Intercept Pharmaceuticals (ICPT) Amid Concerns About No AASLD Presentation of FLINT
-
Gilead (GILD) Should Acquire Intercept (ICPT), Says RBC
-
Notable Analyst Rating Changes 08/12: (ANF) (ICUI) (DF) Upgraded; (AMCC) (WHX) (TCK) Downgraded